





31 2003

TECHCEUTT 16.13 PAGENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Emily Holmes, Reg. No. 40,652

May 22, 2000
Date of Deposit

Applicant: Feng, et al.

Serial No.: 09/194,889

Filed: August 23, 1999

Title: DIAGNOSTIC AND THERAPEUTIC

METHODS RELATED TO REGULATING ENERGY MOBILIZATION WITH OB PROTEIN AND OB ANTIBODIES

Our Ref.: TSRI 540.1

Group Art Unit: 1646

Examiner: G. Draper

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR \$1.821-1.825 mailed December 22, 1999, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR \$1.821 - \$1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR \$1.821(e), on which the Sequence Listing is labeled SCR1832S.APP.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with $37\ CFR\ \$1.821(a)$ through (c) and (e), respectively, are the

same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

5/22/00 Date

Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE 10550 North Torrey Pines Road Mail Drop TPC-8
La Jolla, California 92037 (858) 784-2937

LL\C:\WP\SEQ\SCR1832R.NTC

RECEIVED?

COSSIDER 18 LOSSE



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

·
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An <u>Initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).
tor questions regarding compliance to these requirements.
For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856
PI FASE PETUDIA - 0.000